|
BMD measurements
|
Placebo control group (n = 25)
|
Alendronate group (n = 22)
|
|---|
| | |
Baseline
|
6-month
|
12-month
|
% difference +
|
Baseline
|
6-month
|
12-month
|
% difference +
|
|
DXA (g/cm2)
|
Spine (L2-L4)
|
0.718 ± 0.101
|
0.709 ± 0.105
|
0.710 ± 0.102
|
-0.7 ± 3.3
|
0.719 ± 0.097
|
0.743 ± 0.101 *
|
0.756 ± 0.094 **
|
5.1 ± 4.2 a
|
| |
Femoral Neck
|
0.631 ± 0.060
|
0.633 ± 0.053
|
0.632 ± 0.055
|
-0.1 ± 4.1
|
0.653 ± 0.121
|
0.658 ± 0.129
|
0.670 ± 0.129 **
|
2.5 ± 3.2 b
|
|
pQCT (mg/cm3) Distal radius
|
tBMD
|
138.6 ± 29.3
|
135.3 ± 31.5
|
137.3 ± 31.9
|
-0.6 ± 6.4
|
126.8 ± 46.4
|
130.4 ± 44.3 *
|
130.8 ± 44.5 *
|
0.9 ± 5.1
|
| |
iBMD
|
424.5 ± 73.0
|
421.0 ± 75.6
|
429.9 ± 82.3
|
0.1 ± 3.2
|
388.1 ± 79.4
|
383.4 ± 79.6
|
385.4 ± 91.0
|
0.2 ± 3.8
|
| |
cBMD
|
1124.2 ± 172.9
|
1070.7 ± 289.3
|
1113.0 ± 178.4 **
|
-1.4 ± 2.2
|
1084.3 ± 202.8
|
1024.7 ± 329.8
|
1077.6 ± 203.3
|
0.1 ± 2.4 b
|
- +: percentage compared between baseline and 12-month
- * p < 0.05; **p < 0.01: compared with baseline
- a: p < 0.01; b: p < 0.05: compared for changes in BMD between Alendronate and placebo control group
